文献速递免疫规划卫生政策与健康促进

世界卫生组织第三届疫苗产品开发咨询委员会(PDVAC)会议报告,日内瓦,2016年6月8日至10日

Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.
PubMed 文献 · Vaccine · 2017-03-03

世界卫生组织疫苗产品开发咨询委员会(PDVAC)于2016年6月召开第三次会议,回顾自2015年会议以来有显著进展的病原体领域,并考虑其他病原体疫苗开发的新进展。会议讨论了疟疾和登革热疫苗的监管批准、呼吸道合胞病毒(RSV)疫苗候选在老年人和孕妇中启动的首项III期试验,以及中东呼吸综合征冠状病毒(MERS CoV)和寨卡病毒等新发病原体的疫苗开发工作。PDVAC还计划与免疫战略咨询专家组(SAGE)合作,考虑疫苗推荐和实施所需的数据,以缩短疫苗批准与影响之间的延迟。

要点

  • 疟疾和登革热疫苗已获监管批准,RSV疫苗候选在老年人和孕妇中启动首项III期试验。
  • PDVAC支持MERS CoV和寨卡病毒等新发病原体的疫苗开发,并关注肠道病毒71型(EV71)疫苗在中国的上市。
  • PDVAC将与SAGE合作,考虑疫苗推荐和实施的数据需求,以缩短批准与影响间的延迟。

核心结论

  • PDVAC会议回顾了疟疾、登革热、RSV、HIV、结核、诺如病毒等疫苗的进展,并支持新发病原体疫苗开发。
  • PDVAC将考虑疫苗推荐和实施的数据需求,以缩短疫苗批准与影响之间的延迟。

研究设计与样本

  • 世界卫生组织疫苗产品开发咨询委员会(PDVAC)第三次会议报告,会议于2016年6月8日至10日在日内瓦召开。

主要发现

  • 疟疾和登革热疫苗已获监管批准,RSV疫苗候选在老年人和孕妇中启动了首项III期试验。
  • PDVAC支持MERS CoV和寨卡病毒等新发病原体的疫苗开发工作。
  • HIV和结核疫苗候选的试验稳步进展,诺如病毒疫苗候选已进入IIb期效力研究。
  • 中国近期批准了肠道病毒71型(EV71)疫苗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The third meeting of WHO's Product Development for Vaccines Advisory Committee (PDVAC) was held in June 2016, with a remit to revisit the pathogen areas for which significant progress has occurred since recommendations from the 2015 meeting, as well as to consider new advances in the development of vaccines against other pathogens. Since the previous meeting, significant progress has been made with regulatory approvals of the first malaria and dengue vaccines, and the first phase III trials of a respiratory syncytial virus (RSV) vaccine candidate has started in the elderly and pregnant women. In addition, PDVAC has also supported vaccine development efforts against important emerging pathogens, including Middle Eastern Coronavirus (MERS CoV) and Zika virus. Trials of HIV and tuberculosis vaccine candidates are steadily progressing towards pivotal data points, and the leading norovirus vaccine candidate has entered a phase IIb efficacy study. WHO's Immunization, Vaccine and Biologicals (IVB) department is actively working in several pathogen areas on the recommendation of PDVAC, as well as continuing horizon scanning for advances in the development of vaccines that may benefit low and middle income countries (LMICs), such as the recent licensure of the enterovirus 71 (EV71) vaccine in China. Following on from discussions with WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, PDVAC will also look beyond licensure and consider data needs for vaccine recommendation and implementation to reduce the delay between vaccine approval and vaccine impact.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Giersing BK, Vekemans J, Nava S, et al. Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016. Vaccine. 2017. PMID: 28262332. doi:10.1016/j.vaccine.2016.10.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。